Rapt Therapeutics reports Q1 EPS (8c), consensus (14c)

“The year is off to a great start. We believe RPT904 has the potential to be a best-in-class option to treat patients with food allergy and are making good progress toward our planned initiation of a Phase 2b trial in the second half of 2025,” said Brian Wong, President and CEO of RAPT. “We are also excited about RPT904’s potential as a treatment for patients with chronic spontaneous urticaria and look forward to clinical data later this year from our partner Jemincare to guide our development strategy in CSU.”